2 recruiting, 1 terminated. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Vulvar HSIL: new trials by email Literature Review of Vulvar HSIL trials Research Report on Vulvar HSIL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL Gardasil 9 Suspension for Injection, Placebo - Vulvar HSIL, HPV | Phase 4 | Recruiting | Erasmus Medical Center | 500 | 2024-03-01 | 2026-09-15 |
| Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) Artesunate ointment, Placebo ointment - Vulvar Diseases, HPV Infection | Phase 2 | Recruiting | Frantz Viral Therapeutics, LLC | 27 | 2023-12-06 | 2025-08-14 |
| Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions E7 T Cell Receptor (TCR) - Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2019-10-09 | 2021-04-13 |
Papillomavirus Infections (2) · Neoplasms, Squamous Cell (1) · Vulvar Diseases (1)
Communicable Diseases (2) · DNA Virus Infections (2) · Disease Attributes (2) · Genital Diseases (2) · Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2) · Tumor Virus Infections (2) · Urogenital Diseases (2) · Virus Diseases (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases, Female (1)
Injections (1) · artemisinin (1) · artenimol (1) · artesunic acid (1)
Erasmus Medical Center (1) · Frantz Viral Therapeutics, LLC (1) · National Cancer Institute (NCI) (1)
United States (2) · Netherlands (1)
2023 (1)